Perspectives by the Leerink Center for Pharmacoeconomics
Perspectives by the Leerink Center for Pharmacoeconomics
Podcast Description
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
Podcast Insights
Content Themes
The podcast focuses on healthcare innovations, cost-effectiveness analysis, and the societal impact of health policies, with episodes including discussions on Generalized Cost Effectiveness Analysis (GCEA) and communication strategies for health impacts. Specific themes also cover the intersection of health journalism and economics.

Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr. Mel Whittington, a health economist and Head of the Center for Pharmacoeconomics, we will be hearing from individuals across the industry to better understand and appreciate the societal impact of healthcare innovations.
What do Europe’s changing pharmaceutical policies mean for the economics of drug development? In this episode of Perspectives, Mel Whittington speaks with Graham Cookson, CEO of the Office of Health Economics, to discuss three major developments impacting the European life sciences landscape: joint clinical assessment (JCA), the EU Pharma Package, and most-favored-nation (MFN) pricing.
Graham explains how JCA impacts the way comparative clinical evidence is generated and assessed across Europe and the importance of planning for it before pivotal trials are designed. He also gets into how the EU Pharma Package may shift incentives. The conversation then turns to MFN pricing and the tension between fast, broad access and increasing global price exposure.
Topics discussed include:
- How JCA may affect clinical development and evidence requirements
- The EU Pharma Package’s proposed changes to data and market protection
- Implications for orphan drugs, breakthrough products, and areas of unmet need
- The interaction between JCA, the EU Pharma Package, and MFN pricing
- Why companies may “delay, run, or hide”
Show Links:
- Overview of JCA: One Europe, one assessment? Unpacking the European Joint Clinical Assessment – OHE
- Lessons learned from the first JCA: What the first EU JCA reveals about assessing precision oncology – OHE
- What JCA might mean for orphan drugs: Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicin…
- A global impact framework on MFN: MFN’s global ripple effects: what they mean for manufacturers, payers, patients and policymakers – Change Initiative
- Access considerations in the shadow of MFN: Global equity in the shadow of US pricing reform: Access by bargaining power? | Insights from a WHS side event – OHE
- US pricing negotiations with Germany: Germany’s drug-pricing dilemma: Why Europe’s pivotal market holds the key to the MFN debate – OHE

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.